Prediction of age-related macular degeneration in the general population: the Three Continent AMD Consortium.

[1]  Gabriëlle H S Buitendijk,et al.  Harmonizing the Classification of Age-related Macular Degeneration in the Three-Continent AMD Consortium , 2014, Ophthalmic epidemiology.

[2]  Gabriëlle H S Buitendijk,et al.  Seven New Loci Associated with Age-Related Macular Degeneration , 2013, Nature Genetics.

[3]  E. Makalic,et al.  Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. , 2013, Ophthalmology.

[4]  B. J. Klevering,et al.  Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration. , 2012, Ophthalmology.

[5]  J. Jonas,et al.  Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration. , 2012, Ophthalmology.

[6]  I. Heid,et al.  Modelling the Genetic Risk in Age-Related Macular Degeneration , 2012, PloS one.

[7]  M. Daly,et al.  Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. , 2012, Investigative ophthalmology & visual science.

[8]  B. J. Klevering,et al.  Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. , 2012, Ophthalmology.

[9]  Frederick L Ferris,et al.  Risk assessment model for development of advanced age-related macular degeneration. , 2011, Archives of ophthalmology.

[10]  Johanna M Seddon,et al.  Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors. , 2011, Ophthalmology.

[11]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[12]  M. Arfan Ikram,et al.  The Rotterdam Study: 2012 objectives and design update , 2011, European journal of epidemiology.

[13]  A. Bansal,et al.  Clinical validation of a genetic model to estimate the risk of developing choroidal neovascular age-related macular degeneration , 2011, Human Genomics.

[14]  A. Hofman,et al.  Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and ω-3 fatty acids: the Rotterdam study. , 2011, Archives of ophthalmology.

[15]  Robert B Wallace,et al.  Healthy lifestyles related to subsequent prevalence of age-related macular degeneration. , 2011, Archives of ophthalmology.

[16]  Margaret A. Pericak-Vance,et al.  Using Genetic Variation and Environmental Risk Factor Data to Identify Individuals at High Risk for Age-Related Macular Degeneration , 2011, PloS one.

[17]  John P. A. Ioannidis,et al.  Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration , 2011, European Journal of Human Genetics.

[18]  M. Goldbaum,et al.  Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. , 2011, Archives of ophthalmology.

[19]  G. Ying,et al.  Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial. , 2011, Ophthalmology.

[20]  Yang Wang,et al.  Genome-wide association identifies SKIV2L and MYRIP as protective factors for age-related macular degeneration , 2010, Genes and Immunity.

[21]  S. Ennis,et al.  Determination of a gene and environment risk model for age-related macular degeneration , 2010, British Journal of Ophthalmology.

[22]  C. Patterson,et al.  Complement Component 3: an assessment of association with AMD and analysis of gene-gene and gene-environment interactions in a Northern Irish cohort , 2010, Molecular vision.

[23]  S. Hawken,et al.  A genetic approach to stratification of risk for age-related macular degeneration. , 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[24]  B. Rosner,et al.  Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. , 2009, Investigative ophthalmology & visual science.

[25]  Johanna M Seddon,et al.  Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. , 2009, Investigative ophthalmology & visual science.

[26]  R. Klein,et al.  Dietary compound score and risk of age-related macular degeneration in the age-related eye disease study. , 2009, Ophthalmology.

[27]  Daniel E. Weeks,et al.  Interpretation of Genetic Association Studies: Markers with Replicated Highly Significant Odds Ratios May Be Poor Classifiers , 2009, PLoS genetics.

[28]  Monique M. B. Breteler,et al.  The Rotterdam Study: 2016 objectives and design update , 2015, European Journal of Epidemiology.

[29]  D. Weeks,et al.  C2 and CFB Genes in Age-Related Maculopathy and Joint Action with CFH and LOC387715 Genes , 2008, PloS one.

[30]  P. Mitchell,et al.  Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. , 2008, Ophthalmology.

[31]  M. Brantley,et al.  Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. , 2007, Ophthalmology.

[32]  N. Orr,et al.  Neovascular Age-Related Macular Degeneration Risk Based on CFH, LOC387715/HTRA1, and Smoking , 2007, PLoS medicine.

[33]  A. Hofman,et al.  Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. , 2006, JAMA.

[34]  Usha Chakravarthy,et al.  Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). , 2006, Archives of ophthalmology.

[35]  R. T. Smith,et al.  Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration , 2006, Nature Genetics.

[36]  A. Hofman,et al.  Dietary intake of antioxidants and risk of age-related macular degeneration. , 2005, JAMA.

[37]  V. Sheffield,et al.  Missense variations in the fibulin 5 gene and age-related macular degeneration. , 2004, The New England journal of medicine.

[38]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[39]  A. Hofman,et al.  REVIEW: Epidemiology of age-related maculopathy: a review , 2003, European Journal of Epidemiology.

[40]  A. Hofman,et al.  Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.

[41]  Albert Hofman,et al.  Epidemiology of age-related maculopathy: a review. , 2003, European journal of epidemiology.

[42]  A Hofman,et al.  Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. , 1998, Archives of ophthalmology.

[43]  M. Szklo,et al.  Population-based cohort studies. , 1998, Epidemiologic reviews.

[44]  A. Hofman,et al.  Smoking is also associated with age-related macular degeneration in persons aged 85 years and older: The Rotterdam Study. , 1997, Archives of ophthalmology.

[45]  J M Seddon,et al.  Familial aggregation of age-related maculopathy. , 1997, American journal of ophthalmology.

[46]  A. Hofman,et al.  Age-related macular degeneration and smoking. The Rotterdam Study. , 1996 .

[47]  J. J. Wang,et al.  Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. , 1995, Ophthalmology.

[48]  P T de Jong,et al.  An international classification and grading system for age-related maculopathy and age-related macular degeneration , 1995 .

[49]  R. Klein,et al.  The Beaver Dam Eye Study: visual acuity. , 1991, Ophthalmology.

[50]  R. Klein,et al.  The Wisconsin age-related maculopathy grading system. , 1991, Ophthalmology.

[51]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .

[52]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.